AAV for pain: steps towards clinical translation (Q37406976)

20 August 2017

1 reference

title

AAV for pain: steps towards clinical translation (English)

1 reference

20 August 2017

A S Beutler

1

1 reference

PubMed ID

19262609

20 August 2017

M Reinhardt

series ordinal

2

1 reference

20 August 2017

5 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

16

1 reference

20 August 2017

461-469

1 reference

20 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2009.23

20 August 2017

0 references

cites work

Pain and its treatment in outpatients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Multicentre study of cancer pain and its treatment in France

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Understanding the experience of pain in terminally ill patients.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Pharmacologic treatment of cancer pain

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

A 44-year-old woman with severe pain at the end of life.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Epidemiology of adenovirus-associated virus infection in a nursery population

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Manufacturing and characterizing AAV-based vectors for use in clinical studies

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Toward exascale production of recombinant adeno-associated virus for gene transfer applications

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Large-scale production of recombinant adeno-associated viral vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Adeno-associated virus integration: virus versus vector

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

AAV vector integration sites in mouse hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Immune responses to AAV capsid: are mice not humans after all?

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Immune responses to AAV in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

CD8(+) T-cell responses to adeno-associated virus capsid in humans

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Effect of gene therapy on visual function in Leber's congenital amaurosis

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Safety and efficacy of gene transfer for Leber's congenital amaurosis

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Retrovirus-mediated expression of an artificial beta-endorphin precursor in primary fibroblasts.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Safety evaluation of intrathecal substance P-saporin, a targeted neurotoxin, in dogs

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: a strategy to increase opioid antinociception

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.23

7 January 2021

Identifiers

DOI

10.1038/GT.2009.23

1 reference

20 August 2017

1 reference

PubMed ID

19262609